ProPhase Labs Stock Performance

PRPH Stock

USD 0.14 -0.01 -6.67%

ProPhase Labs' total-return profile spans short-term moves to multi-year compounding. Based on the 3 months horizon, ProPhase Labs shows an expected return of 0.45%.

Risk-Adjusted Performance

0100

3 · Mild

Risk-adjusted returns for ProPhase Labs fall below 3% of the global equities and portfolios universe across the last 90 days. At micro-cap scale, institutional coverage and secondary-market liquidity are typically well established. Over recent months, ProPhase Labs has shown strength in converting risk exposure into positive shareholder returns. Learn More

Relative Risk vs. Return Landscape

If you had invested $ 100.05 in ProPhase Labs on February 6, 2026 and sold it today, you would have lost $ 6.67 , a decline of 6.67% over 90 days. ProPhase Labs is currently generating a 0.448% daily expected return and carries 10.51% risk (volatility on return distribution) over a 90-day horizon. In relative terms, ProPhase Labs exhibits above-average volatility, exceeding roughly 6% of comparable stocks, and PRPH has trailed 91% of traded instruments in return over the 90-day horizon.

Expected Return

Risk

This benchmark view frames the instrument through return capture and volatility trade-offs. It works best as a comparative read on return quality, drawdown exposure, and volatility burden. Given a 90-day horizon, PRPH generates 11.33 times more return on investment than the market. However, PRPH exhibits significantly elevated volatility relative to the market, which is typical for low-priced or thinly traded securities. Its risk-adjusted efficiency stands at about 0.04% per unit of risk. Dow Jones Industrial is currently generating roughly 0.0% per unit of risk.

Target Price Odds to finish over Current Price

The concept of mean reversion, where ProPhase Labs Stock price gravitates toward equilibrium, is fundamental to market analysis. This pattern is a cornerstone of many forecasting models, though periods of persistent mispricing occur.

Current Price	Horizon	Target Price	Odds moving above the current price in 90 days
0.14	90 days	0.14	about 37.15 %

Statistical modeling indicates that the probability of ProPhase Labs moving above the current price in 90 days from now is about 37.15 %. The historical return profile over this window has produced more above-current than below-current outcomes. (This stock distribution maps the range in which ProPhase Labs Stock has been most likely to trade over the next 90 days).

Given a 90-day horizon, ProPhase Labs has a beta of 0.0023 indicating as returns on the market go up, ProPhase Labs's average returns tend to increase less than the benchmark. However, during a bear market, the loss from holding ProPhase Labs tends to be smaller as well. Additionally, ProPhase Labs has an alpha of 0.5513, implying that it can generate a 0.5513 percent excess return over Dow Jones Industrial after adjusting for the inherent market risk (beta).

ProPhase Labs Price Density

Price

Predictive Modules for ProPhase Labs

Accurately predicting the stock market is one of the most challenging tasks for investors analyzing ProPhase Labs. No single approach dominates, but the practice of forecasting remains an essential element of the investment process.

Mean reversion setups in ProPhase Labs emerge when price has deviated materially from its long-run average. Sentiment extremes, news events, or liquidity shocks are common catalysts for these temporary dislocations in ProPhase Labs.

Sentiment

Range

Low	Sentiment	High
0.01	0.14	10.65

Details

Intrinsic

Valuation

Low	Intrinsic	High
0.01	0.11	10.62

Details

Naive

Forecast

Low	Next	High
0.0026	0.13	10.64

Details

Bollinger

Band Projection (param)

Lower	Middle Band	Upper
0.08	0.12	0.17

Details

This analysis measures ProPhase Labs's competitive standing across key financial and valuation dimensions. Relative margins, returns, and growth rates indicate whether ProPhase Labs' valuation reflects competitive positioning.

Primary Risk Indicators

Volatility has been a defining feature of the stock market in recent decades, and ProPhase Labs has reflected that pattern. Sudden corrections and sharp rallies have tested many portfolios that include ProPhase Labs.

α	Alpha over Dow Jones	0.55	Details
β	Beta against Dow Jones	0.0023	Details
σ	Overall volatility	0.03	Details
Ir	Information ratio	0.05	Details

Investor Alerts and Insights

For investors following ProPhase Labs, automated alerts provide early signals of meaningful shifts in stock dynamics. ProPhase Labs notifications highlight material changes that could affect portfolio decisions and aggregate risk exposure.

	ProPhase Labs had very high historical volatility over the last 90 days
	ProPhase Labs has some characteristics of a very speculative penny stock
	ProPhase Labs has high likelihood to experience some financial distress in the next 2 years
	PRPH reported previous year's revenue of $6.77 million. Net Loss for the year was -$49.52 million with profit before overhead, payroll, taxes, and interest of $1.94 million.
	ProPhase Labs currently holds about $27.5 million in cash as of latest reporting with -$17.54 million of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow.

Price Density Drivers

For ProPhase Labs, price shifts are largely a function of buyer and seller positioning dynamics and broader market conditions. Key market indicators for ProPhase Labs Stock are presented below to contextualize recent price movements.

	Common Stock Shares Outstanding	1.91 million
	Cash And Short Term Investments	678,000

ProPhase Labs Fundamentals Growth

The pricing of ProPhase Labs Stock is heavily influenced by ProPhase Labs' fundamental performance over time. Investors monitor revenue growth, profit margins, cash flow generation, and debt management as key indicators.

	Current Valuation	7.92 M
	Shares Outstanding	4.74 M
	Earnings Per Share	-21.93 X

Performance Metrics & Calculation Methodology

ProPhase Labs risk-adjusted performance measures whether returns compensate for the volatility borne by holders. Return per unit of risk provides a more stable comparison across instruments and regimes. ProPhase Labs shows ROE of -3.59%, ROA of -16.64% (TTM).

Reported values for ProPhase Labs are derived from periodic company reporting and market reference feeds and standardized for analysis. Return and risk statistics are calculated from historical price series.

Editorial review and methodology oversight provided by: Ellen Johnson, Member of Macroaxis Editorial Board